Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Nov 22, 2021 5:48pm
530 Views
Post# 34154729

RE:RE:RE:Pfizer & BioNTech partnership

RE:RE:RE:Pfizer & BioNTech partnershipI'm sure this has been posted before!  

Graduation

 
 
 
 

Many companies that list on TSXV eventually grow to meet the listing requirements of TSX and choose to graduate to the senior board. Hundreds of companies have followed this path. In fact, one in five companies in the S&P/TSX Composite Index are graduates of TSXV.

Once your company is ready, we can help your company graduate to TSX in an efficient and economical manner. Consider these benefits of graduation:

Cost savings

  • TSX listing application fee (CDN$10,000) will be waived for eligible TSXV issuers. Original Listing Fees will still apply.

Reduction of documentation

  • Certain issuer information on file with TSXV can be accessed by TSX, reducing the number of documents required to be submitted.

Waiver of sponsorship

  • Sponsorship requirements may be waived for qualified TSXV issuers.*

Once listed on TSX, additional benefits may include:

  • Increased access to capital
  • Enhanced reputation from meeting the minimum standards of a senior exchange board
  • Greater visibility – TSXV graduates listed on TSX are covered by an average of five analysts
  • Access to institutional capital – institutional investors have invested $15 Billion in TSXV graduates
  • Enhanced liquidity on world markets – roughly 40% of TSX trading is originated by international headquartered Investment Dealers
  • Escrow policies may be reduced upon graduation to TSX
  • Improved M&A opportunities
  • A TSX listing is a requirement for inclusion in the majority of indices and composites

*Some conditions apply. See Part III and Appendix A of the Toronto Stock Exchange Company Manual for complete details.

Please see our Graduation Information Sheet for more information. 

For more information on the graduation process, contact Business Development.


CancerSlayer wrote 

 

Infinity wrote: Agree,  a joint venture is the best case scenario.  There is no way that Biontech could have acheived worldwide marketing of their vaccine without Pfizer, not a chance..
However, to establish a really good joint venture, you need to have 
1.  Excellent Clinical Test results.  Peer reviews of other Urological Oncologists who specialise in Blader cancer treatment.  
2.  The share price has to move closer to the $ 5.00 mark to establish a joint venture that is favourable to the Share holders.
3.  To achieve this goal,  we need to have TLT listed in TSX, Nasdaq, or NYSE.   To be listed in the larger exchanges the share price and market cap has to move up....
4.  Everything hinges on the Clinical Test results and obtaining Break through Designation,,,
I truly believe, we are close to achieving this Goal and RDW is biding his time so that we can all get a joint venture under favourable terms.

When it comes to time frame, my guess is that we are still 1 to 2 years away from a joint venture.  We will very likely have good results from the Vaccine side and that should ease the cash flow requirments to last  the 2 years time frame. 

In the mean time,  if we have someone really talented leading the device marketing team for the Laser,  we should be able to achieve the goals sooner....TLT may even spin off the Laser division completely to concentrate on the Anti cancer and the Vaccine research..
Any which way you look at it, TLT is poised to grow and take off within the next two years time...IMO

 

 

 

Agree....a JV would be ideal, & not until we are FDA approved for this indication, on a real exchange & preferably sitting at least in the $5-10 range.  The real question is, how do we reasonably get there?  

A BTD is a significant milestone achievement.  Though on this exchange, I expect it would lead to one small step-up in share price, yet one giant leap away from a worthwhile up listing (Nasdaq, etc.) imo.  Remaining parked on this exchange until drug approval may be the best option...more shares to accumulate, which works for me.


<< Previous
Bullboard Posts
Next >>